Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Articles

Vol. 1 No. 2 (2010): April– June 2010

Inhibition of HIV Replication and Integrase Activity by4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)amino]- N-(4,6-dimethyl-2-pyrimidinyl)-Benzenesulphonamide and Derivatives

DOI
https://doi.org/10.37285/ijddd.1.2.8
Submitted
November 24, 2024
Published
2010-05-15

Abstract

e evaluated the broadspectrum antiretroviral activity of 4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)amino]-N-(4,6-dimethyl-2-pyrimidinyl)-benzene sulphonamide and its derivatives using different strains of HIV-1, HIV-2 and SIV. Several SPIII derivatives were found to inhibit HIV-1 (IIIB and NL4.3) replication in MT-4 cells at EC50 values ranging from 3.6 to 49.6 µg/ml. No cytotoxicity was observed at concentrations up to 125 µg/ml in mock-infected MT-4 cells. The compounds were evaluated for their inhibitory effects against a variety of mutant HIV strains. The SPIII derivatives showed low level resistance (up to 11-fold) to NL4.3 virus strains resistant to agents that block virus entry, i.e. NL4.3 strains resistant to the binding inhibitor dextran sulphate or the CXCR4 antagonist AMD3100. Moreover, the SPIII-5Br and 5Cl derivatives showed some low level cross-resistance to an integrase inhibitorresistant virus. We observed no cross-resistance against the fusion inhibitor, nucleoside reverse transcriptase, nonnucleoside reverse transcriptase or protease inhibitor resistant HIV strains. The SPIII compounds were found to inhibit the human immunodeficiency virus type 1 integrase enzymatic activity, HIV-1 integrase binding to target DNA and adsorption of HIV-1 to MT-4 cells, all at IC50 values in the µg/ml range. We conclude that it would be interesting to synthesize and evaluate more derivatives of SPIII to identify more selective congeners. These compounds would enable us to determine the structural requirements for inhibition of entry or integration steps in the replication cycle of HIV.

References

  1. [1] Popp, F.D. J. Pharm. Sci 1969, 12, 182.
  2. [2] Bauer, D.J.; Sadler, P.W.; Br. Pharm. Chemother. 1960, 15, 101.
  3. [3] Bauer, D.J. In: Chemotherapy of Virus Diseases Vol. 1, International Encyclopedia of Pharmacology, Pergamon Press, Oxford, pp. 1972 35-45.
  4. [4] Levinson, W. In: Carter, W.A. (Ed.), Selective inhibitors of viral functions. CRC Press Cleveland, 1973, 213.
  5. [5] Teitz, Y.; Ronen, D. Antimicrob. Agents Chemother 1984, 26, 913.
  6. [6] Teitz, Y.; Ronen, D.; Stematsky, T,; Rigg. J.L. Antiviral Res 1994, 24, 305.
  7. [7] Sriram, D.; Yogeeswari, P.; Meena, K. Pharmazie. 2006, 61, 274.
  8. [8] Pandeya, S.N.; Sriram, D.; De Clercq E.; Pannecouque,C.; Witvrouw, M. Indian. J. Pharm. Sci. 1998, 60, 207.
  9. [9] Pandeya, S.N.; Yogeeswari, P.; Sriram, D.; De Clercq E.; Pannecouque, C,; Witvrouw, M. Chemotherapy 1999, 45, 192.
  10. [10] Pandeya, S.N.; Sriram, D.; Nath, G.; De Clercq E. Farmaco 1999, 54, 624.
  11. [11] Pandeya, S.N.; Sriram, D.; Nath, G.; De Clercq E. Eur.J. Pharm. Sci. 1999 ,9, 25.
  12. [12] Pandeya, S.N.; Sriram, D.; Nath, G.; De Clercq E. Pharm. Acta Helv 1999, 74, 11.
  13. [13] Pandeya, S.N.; Sriram, D.; Nath, G.; De Clercq E. Arzneimittelforschung 2000, 50, 55.
  14. [14] Pandeya, S.N.; Sriram, D.; Nath, G.; De Clercq E. Eur.J. Med. Chem. 2000, 35, 249.
  15. [15] Selvam, P.; Chandramohan, M.; De Clercq, E.; Pannecouque, C.; Witrouw, M. Eur. J. Pharm. Sci. 2001, 14, 313.
  16. [16] Selvam, P.; Murugesh, N.; Chandramohan . M.; De Clercq, E. Indian J. Pharm. Sci., 2004, 66, 465.
  17. [17] Selvam, P.; De Clercq, E. Asian Journal of Chemistry, 2005, 17, 443.
  18. [18] Horwitz, J.P.; J. Chua, M.; Noel, M. J. Org. Chem. 1964, 29, 2076.
  19. [19] Bridger, G. J.; Thornton, D.; Padmanabhan, S.; Martellucci, S.A.; Henson, G.W.; Abrams, M.J.; Yamamoto, N.; De Vreese, K.; Pauwels. R. J. Med. Chem. 1995, 38, 366.
  20. [20] Popovic, M.; Sarngadharan, M.G.; Read, E.; Gallo. R.C.; Science 1984, 224, 497.
  21. [21] Adachi, A.; Gendelman, H.; Koenig, S.; Folks, T.; Willey, R.; Rabson, A.; Martin. M. J.Virol. 1986, 59, 284.
  22. [22] Barré-Sinoussi, F.; Chermann, J.C.; Rey, F.; Nugeyre,
  23. M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vézinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Science 1983, 220, 868.
  24. [23] Rey, M.A.; Krust, B.; Laurent A.G.; Guetard D.; Montagnier, L.; Hovanessian, A.G. Virology, 1989, 173, 258.
  25. [24] Daniel, M.D.; Letvin, N.L.; Sehgal, P.K.; Hunsmann, G.; Schmidt, D.K.; King, N.W.; Desrosiers. R.C.; J. Gen. Virol. 1987, 68, 3183.
  26. [25] Miyoshi, I.; Taguchi, H.; Kobonishi, I.; Yoshimoto, S.; Ohtsuki, Y.; Shiraishi, Y.; Akagi. T. Gann. Monogr 1982, 28, 219.
  27. [26] Larder B.A.; Kemp S.D. Science. 1985, 246, 1155.
  28. [27] Junker, U.; Baker, J.; Kalfoglou, C.S.; Veres, G.; Kaneshima, H.; AIDS Res Hum Retroviruses 1989, 13, 1395.
  29. [28] Nunberg, J.H.; Schleif, W.A.; Boots, E.J.; O'Brien, J.A.; Quintero, J.C.; Hoffman, J.M.; Emini E.A.; Goldman,M. E.. J Virol 1991, 65, 4887.
  30. [29] Hara, H.; Fujihashi, T.; Sakata, T.; Kaji A.; Kaji H. AIDS Res Hum Retroviruses 1997; 13: 695-705
  31. [30] Condra, J.H.; Schleif, W.A.; Blahy, O.M.; Gabryelski,L.J.; Graham, D.J.; Quintero, J.C.; Rhodes, A.; Robbins,H.L.; Roth, E.; Shivaprakash, M. Nature 1995, 374, 569.
  32. [31] De Vreese, K.; Kofler-Mongold, V.; Leutgeb C.; Weber, V.; Vermeire, K.; Schacht, S.; Anné, J.; De Clercq, E.; Datema, R.; Werner, G. J. Virol. 1996, 70, 689.
  33. [32] Esté, J.A.; Schols, D.; De Vreese, K.; Van Laethem, K.; Vandamme, A.; -M Desmyter, J.; De Clercq. E. Mol. Pharmacol. 1997, 52, 98.
  34. [33] Fikkert, V.; Cherepanov, P.; Van Laethem, K.; Hantson, A.; Van Remoortel, B.; Pannecouque, C.; De Clercq, E.; Debyser, Z.; Vandamme, A.M.; Witvrouw, M. Antimicrobial Agents Chemother. 2002, 46, 3954.
  35. [34] Fikkert, V.; Van Maele, B.; Hantson, A.; Vercammen, J.; Van Remoortel, B.; Michiels, M.; Pannecouque, C.; De Maeyer, M.; Engelborghs, Y.; De Clercq, E.; Debyser, Z.; Witvrouw, M. J. Virol 2003, 77, 11459.
  36. [35] Witvrouw, M.; Pannecouque, C.; Switzer W.; Folks, T.; De Clercq, E.; Heneine, W. Antiviral Therapy 2004, 9, 57.
  37. [36] Hwang, Y.; Rhodes, D.; Bushman, F. Nucleic Acids Research. 2000, 28, 4892
  38. [37] Van Craenenbroeck, E.; Engelborghs, Y. J Mol Recognit 2000,13, 93.
  39. [38] Van Craenenbroeck, E.; Engelborghs Y.; Biochemistry 1999, 38, 5082.
  40. [39] Van Craenenbroeck, E.; Vercammen, J.; Matthys, G.; Beirlant, J.; Marot, C.; Hoebeke, J.; Strobbe, R.; Engelborghs, Y. Biol Chem 2001, 382, 355.
  41. [40] Vercammen, J.; Maertens, G.; Gerard, M.; De Clercq, E.; Debyser, Z.; Engelborghs, Y. J Biol Chem. 2002, 277, 38045.
  42. [41] Witvrouw, M.; Fikkert, V.; Vercammen, J.; Van Maele, B.; Engelborghs Y.; Debyzer Z. Curr. Med. Chem. Anti-infective agents, 2005, 4,153.